Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2026-03-03 Capital/Financing Update
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from HLB Life Science regarding the 'Acquisition of Convertible Bonds before Maturity' (Put Option exercise). It details the specific bond series (13th), the amount acquired, the reason (Put Option), and the method of settlement. This falls under capital structure and financing updates, specifically related to debt management and capital changes. Given the specific nature of bond buybacks/repayments, it fits best under the 'CAP' (Capital/Financing Update) category.
2026-03-03 Korean
전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from HLB Life Science regarding the 'Acquisition of Convertible Bonds before Maturity'. It details specific financial data related to the company's capital structure, specifically the buyback of its own convertible bonds (13th series). This falls under the category of capital structure changes and financing updates, specifically related to debt instruments.
2026-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (HLB Life Science) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard periodic financial disclosure required by the Korea Exchange (KRX) for listed companies. Since it provides key financial highlights (revenue, operating profit, net income) for the fiscal year ending 2025-12-31, it functions as an Earnings Release (ER) rather than a full Annual Report or a mere announcement of a report. FY 2025
2026-02-20 Korean
증권발행결과(자율공시) (제16회차 EB)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the completion of a private placement of exchangeable bonds (EB). It details the issuance amount, payment date, and confirms the completion of the transaction. This falls under the category of company financing and capital structure updates.
2026-02-20 Korean
전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from HLB Life Science regarding the acquisition of convertible bonds before maturity. It details the specific bond series (13th), the acquisition amount, the acquisition date, and the reason for the acquisition. This falls under capital structure changes and financing updates, specifically related to debt management, which is best classified as a Capital/Financing Update (CAP).
2026-02-19 Korean
타법인주식및출자증권처분결정
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory announcement regarding the disposal of shares in another company (HLB) by HLB Life Science. It details the number of shares, the transaction amount, the purpose (financial structure improvement), and the board resolution date. This type of corporate action disclosure regarding the sale of assets or equity in other entities is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like M&A (which usually implies a merger or acquisition of a business entity) or share buybacks (which would be POS).
2026-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.